Percutaneous Neurostimulation in Knee Osteoarthritis

Percutaneous Peripheral Temporary Neurostimulation in Moderate to Severe Knee Osteoarthritis

Peripheral nerve stimulation (PNS) is a drug-free pain management procedure that uses electrical impulses to target specific nerves and block pain signals. PNS helps decrease perception of pain, providing real answers to patients dealing with chronic knee pain. The case study discussed in this presentation is of the use of PNS targeting the superior lateral genicular nerve and the saphenous nerve for a patient with moderate to severe knee pain from osteoarthritis

Study Overview

• Status: Recruiting
• Conditions: Neuromodulation; Osteoarthritis (OA) of the Knee
• Intervention / Treatment: Device: nerve stimulation using a nerve stimulator to the genicular nerve; Device: nerve stimulation using a nerve stimulator to the saphenous nerve

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Aliaa Mamdouh Abdelaziz Farag, MD; Phone Number: +201069468486; Email: aliaa.mamdouh@med.tanta.edu.eg

Study Locations

• Egypt
  • Tanta, Egypt
    • Recruiting
    • Faculty of medicine, Tanta University
    • Contact: Aliaa Mamdouh Abdelaziz Farag, MD; Phone Number: +201069468486; Email: aliaa.mamdouh@med.tanta.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. adults between the ages of 30 and 70 years with a clinical diagnosis of moderate to severe knee OA who suffered knee pain.
2. Patients who cannot afford intra-articular injections or radiofrequency ablation (RFA).
3. patients who had failed 2 different oral pain medications and 6 weeks of physical therapy.

Exclusion Criteria:

1. Patients with OA show improvement in pain after physiotherapy.
2. patients evaluated by an orthopaedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA.
3. pregnant patients.
4. patients on anticoagulation therapy, who were not permitted to stop anticoagulation.
5. patients with previous trauma, neurological or endocrine diseases like diabetes mellitus, and knee tumors; and patients with inflammatory arthritis.
6. people who had received an intra-articular knee injection within the last 6 months.
7. Patients with tendon tears, bursitis, or calcified tendonitis as proven by imaging.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve block	Device: nerve stimulation using a nerve stimulator to the genicular nerve; temporary transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes.
Experimental: transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve	Device: nerve stimulation using a nerve stimulator to the saphenous nerve; temporary transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
change in visual analogue scale after intervention.	Change (clinical improvement) in visual analogue scale (VAS) immediately after intervention.	immediately after intervention.

Collaborators and Investigators

• Sponsor: Tanta University

Study record dates

Study Major Dates

• Study Start (Actual): June 2, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): November 1, 2026

Study Registration Dates

• First Submitted: June 4, 2026
• First Submitted That Met QC Criteria: June 4, 2026
• First Posted (Actual): June 10, 2026

Study Record Updates

• Last Update Posted (Actual): June 12, 2026
• Last Update Submitted That Met QC Criteria: June 10, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Arthritis; Joint Diseases; Rheumatic Diseases; Osteoarthritis
• Other Study ID Numbers: 36265PR60/5/26

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Plan to Share IPD: "Yes" Plan Description: "Data obtained through this study may be provided to qualified researchers with academic interest in scapular dyskinesis. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e., a material transfer agreement) are prerequisites to the sharing of data with the requesting party.

Results will be published by the investigators in academic journal.

• IPD Sharing Time Frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis
• IPD Sharing Access Criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No